Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2017

View Archived Issues

Anti-CD73 A-001421 shows antitumor activity in experimental tumor models

Novel technique of rapid and robust diagnosis of Alzheimer's disease and various other dementias

TargomiRs demonstrates early signs of activity in patients with malignant pleural mesothelioma

Phase III trial of upadacitinib in rheumatoid arthritis meets all endpoints

Infant Bacterial Therapeutics reports topline safety data from phase II study of IBP-9414

MK-3866 studied in patients with impaired renal function

DelMar Pharmaceuticals commences phase II study of VAL-083 in GBM

EMA grants orphan drug designation to seladelpar for primary biliary cholangitis

New oncolytic measles virus-mediated delivery of PD-1-targeting antibody for cancer treatment

Marinus Pharmaceuticals reports results from phase II study in CDKL5 disorder

BARDA awards contract to Summit Therapeutics to develop ridinilazole for CDI

GSK initiates phase I study of acute pancreatitis treatment GSK-3335065

2017 Lasker awards recognize significance of HPV vaccine, mTOR

East China University of Science and Technology patents EGFR inhibitors

Taiho Pharmaceutical identifies RET inhibitors

DiaMedica Therapeutics begins phase II study of DM-199

Cantargia initiates phase I/II trial of CAN-04 in solid malignant tumors

DENV glycoprotein EDIII variants reported in Albert Einstein College of Medicine patent

Merck KGaA compares MSB-11455 to Neulasta in phase I studies

Global Alliance for TB Drug Development initiates phase I study of TBA-7371

Phase III LIBERTY ASTHMA QUEST study of dupilumab meets primary endpoints

The Osaka University discloses reoviruses for treating fibrosis

New phase I trial evaluates M-3541 with radiotherapy in patients with solid tumors

Bayer enters kidney disease collaboration with Vanderbilt University Medical Center

New malaria trial explores modifications to vaccine regimen of RTS,S

HitGen and Takeda establish drug discovery research collaboration

Canalia launched in Japan for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...